We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Společné stanovisko odborných společností k farmakologické léčbě obezity.
- Authors
Müllerová, D.; Haluzík, M.; Sucharda, P.; Boženský, J.; Fried, M.; Holéczy, P.; Kunešová, M.; Málková, I.; Slabá, Š.; Šrámková, P.; Taxová Braunerová, R.; Hainer, V.
- Abstract
Obesity has become a worldwide pandemic in the last thirty years. Its treatment is primarily based on the life-style changes that, however, often fail in the long-term run. For the next decade, major perspectives in the successful obesity treatment include, in addition to bariatric surgery, a long-term treatment with anti-obesity drugs, in particular the ones that in addition to weight reduction also directly affect obesity-related pathologies. This paper summarizes current possibilities of obesity pharmacotherapy including its indication, proper selection of patients and side effects of anti-obesity drugs. It also reviews the studies describing long-term efficacy and safety of anti-obesity drugs. Despite the availability of efficacious and safe anti-obesity drugs, these therapies are not even partially covered by health insurance. The costs of anti-obesity drugs are for the majority of patients with obesity unacceptably high. The actual unavailability of anti-obesity drugs for patients with obesity has significant health-economic consequences. Limited use of these medications that have evidence-based data supporting their efficacy, contributes to high prevalence of obesity-related pathologies with subsequent low treatment efficacy and high treatment costs. We believe that at least partial reimbursement of anti-obesity drugs from general health insurance, in patients with verified compliance and under clearly defined conditions, is a necessary step to improve this situation which could lead to clearly economically effective results.
- Publication
General Practitioner / Praktický Lékař, 2021, Vol 101, Issue 1, p32
- ISSN
0032-6739
- Publication type
Article